OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Hellmann on the Impact of Systemic Therapy on Surgery in Ovarian Cancer

March 10th 2020

Mira Hellmann, MD, discusses the impact of surgery on patients with ovarian cancer.

Dr. Tsao on Rationale for Staging Renal Cell Carcinoma

March 10th 2020

Che-Kai Tsao, MD, discusses the rationale behind staging disease, especially in the context of when patients are diagnosed with renal cell carcinoma.

Dr. Polsky on the Unmet Need of Clinical Utility in Liquid Biopsy

March 10th 2020

David Polsky, MD, PhD, discusses the unmet need of clinical utility in liquid biopsy.

Dr. Patel on the Unmet Need of FLT3 Inhibitors in AML Treatment

March 10th 2020

Prapti Patel, MD, discusses the unmet need of FLT3 inhibitors in the treatment of patients with acute myeloid leukemia.

Dr. Freedland on the Importance of Conducting Real-World Analyses in Prostate Cancer

March 10th 2020

Stephen J. Freedland, MD, discusses the importance of conducting real-world analyses in prostate cancer.

Dr. Pant on Immunotherapy Combos and Upcoming Developments in Pancreatic Cancer

March 10th 2020

Shubham Pant, MD, discusses combination immunotherapies and upcoming developments in pancreatic cancer.

Dr. Raphael on the CLARITY Trial in CLL

March 10th 2020

Bruce G. Raphael, MD, a clinical professor in the Department of Medicine at NYU Langone Health, discusses the phase II CLARITY trial in chronic lymphocytic leukemia (CLL).

Dr. Garcia on the Managing Thrombocytopenia With Navitoclax in Myelofibrosis

March 10th 2020

Jacqueline S. Garcia, MD, instructor in medicine, Department of Medical Oncology, Harvard Medical School, and physician, Dana-Farber Cancer Institute, discusses the management of thrombocytopenia with navitoclax in patients with myelofibrosis.

Dr. O'Malley on the Optimal Use of PARP Inhibitors in Advanced Ovarian Cancer

March 10th 2020

David O’Malley, MD, professor, Department of Obstetrics and Gynecology, The Ohio State University College of Medicine, and director, Division of Gynecologic Oncology at The Ohio State University Comprehensive Cancer Center–The James, discusses the optimal use of PARP inhibitors as frontline maintenance therapy in patients with advanced ovarian cancer.

The Applications of a Mixed Reality Laboratory

March 7th 2020

Andrea Sboner, MS, PhD, assistant professor of computational genomics in computational biomedicine and of pathology and laboratory medicine, Weill Cornell Medicine, discusses the applications of a mixed reality laboratory.

Dr. Ledermann on Response to Rucaparib in Recurrent Ovarian Cancer

March 7th 2020

Jonathan A. Ledermann, BSc, MD, FRCP, professor of medical oncology, UCL Cancer Institute, University College London, and an honorary consultant medical oncologist, UCL Hospitals, discusses responses to rucaparib (Rubraca) maintenance in ovarian cancer.

Dr. Salani on the Progression of Upfront Ovarian Cancer Treatment

March 7th 2020

Ritu Salani, MD, discusses the progression of upfront ovarian cancer treatment.

Dr. Crew on the APHINITY Trial Results in HER2+ Breast Cancer

March 7th 2020

Katherine D. Crew, MD, MS, discusses the results of the APHINITY trial in HER2-positive breast cancer.

Dr. Grivas on Cabazitaxel/Enzalutamide in mCRPC

March 7th 2020

Petros Grivas, MD, PhD, physician, Seattle Cancer Care Alliance; associate professor, Department of Medicine, Division of Oncology and clinical director of the Genitourinary Cancers Program, University of Washington School of Medicine; and associate member, Clinical Research Division, Fred Hutchinson Cancer Center, discusses the combination of cabazitaxel and enzalutamide (Xtandi) in metastatic castration-resistant prostate cancer (mCRPC).

Dr. Woyach on Treatment Challenges in CLL

March 7th 2020

Jennifer Woyach, MD, discusses current challenges in chronic lymphocytic leukemia treatment.

Dr. Chung on the Rationale of the KEYNOTE-811 Trial in HER2+ Gastric Cancer

March 6th 2020

Hyun C. Chung, MD, PhD, discusses the rationale of the KEYNOTE-811 study in HER2-positive gastric cancer.

Dr. Husain on the Increased Use of and Challenges With Utilizing Liquid Biopsies

March 6th 2020

Hatim Husain, MD, discusses the increased use of and challenges with utilizing liquid biopsies.

Dr. Awan on Utilizing Acalabrutinib in CLL

March 6th 2020

Farrukh Awan, MD, discusses the utilization of acalabrutinib in patients with chronic lymphocytic leukemia.

Dr. Daver on Results of a Combination Study With Azacitidine/Nivolumab in AML

March 6th 2020

Naval G. Daver, MD, discusses the results of a phase Ib/II study that evaluated the combination of azacitidine and nivolumab (Opdivo) in patients with relapsed/refractory acute myeloid leukemia.

Phase I Study With Prexasertib and LY3300054 in Ovarian Cancer

March 6th 2020

Claire Manuszak, BS, discusses a phase I study (NCT03495323) with prexasertib (LY2606368) and LY3300054 in ovarian cancer.